Investing In People: Aligning VCs And Today’s Entrepreneurs
VC Playbook: An Interview With INKEF Capital’s Roel Bulthuis
Executive Summary
In the latest instalment of our VC playbook series, In Vivo sits down with Roel Bulthuis, managing partner at INKEF Capital, to discuss the group’s approach to health care investing in Europe, the importance of funding a team not just a project and how life sciences venture capital is evolving with the emergence of health tech.
You may also be interested in...
Snapshot: Highlights From The First Six Months Of 2020
A selection of features you might have missed from the first six months of 2020, covering key topics from COVID-19 strategies in medtech to an analysis of pipeline focus areas across the pharma sector. Click on each section to get the full story behind the data.
First Vaccine Approval For Janssen With Two-Dose Ebola Prophylactic
The two-part vaccine becomes the second against Ebola to get approval. Janssen is now collaborating with the World Health Organization on vaccine pre-qualification to get it to people in need.
COVID-19 Vaccine Expectations Are Ambitious Not Impossible
Johan Van Hoof, global head of vaccines at Janssen, talks to In Vivo about the company’s platform, how it is approaching COVID-19 research and the impact of today’s global pandemic on the future of vaccine R&D.
Need a specific report? 1000+ reports available
Buy Reports